MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary endpoint; twice-daily dose succeeded vs. placebo.
July 27, 2026 11:17 AM EDT
MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
Ayisha Sharma
News Reporter
MapLight Therapeutics’ stock $MPLT plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage …
MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary…
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with…
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication…
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.
Minoryx's leriglitazone (Nezglyal) won EU backing after two prior rejections, while CHMP rejected Zevra's arimoclomol (Meplyffa).
